Popular on Innoget
Publications
- View more
 | Seeking technologies to reduce GHGs in all aspects of the supply chain and manufacturing process. |
|
PepsiCo is committed to reducing GHG emissions from seed to shelf. We are looking to engage with partners who can assist us in our goal of reducing GHG 20% by 2030 and achieving net-zero emissions by 2050. As new technologies emerge, efficiencies will be gained and PepsiCo aims to remain at the forefront of best practices in the food and beverage industry. PepsiCo is seeking technologies to reduce GHGs in all aspects of the supply chain and manufacturing process. Solutions may be in one or more of the following areas: • Agriculture – sustainable farming and the reduction of GHG intensive fertilizers • Manufacturing – adopting energy efficient manufacturing processes; novel methods for utilizing waste; use of renewable thermal energy at scale • Packaging – alternative packaging materials and formats that reduce GHGs • Distribution – technologies to assist in the efficiency of our company-owned and third party fleet |
| | Seeking Recycling technologies for biodegradable films |
|
We are looking for solutions to convert bio-based packaging back to starting materials or other high-value added chemicals (no fuels). |
| | Seeking Recyclable Closure for Paper Beverage Bottles |
|
We are seeking technologies for a re-closable fiber-based closure for a paper beverage bottle that can be recycled in the paper stream. |
 | LIH383: novel modulator of the opioid system regulator ACKR3 |
|
LIH383 is a novel highly potent and specific negative modulator of ACKR3, developed by Dr Andy Chevigné, Head of Immunopharmacology and Interactomics, and Dr Martyna Szpakowska. It is an octapeptide (short chain of eight amino acids) with high selectivity and subnanomolar affinity for ACKR3. It was engineered by introducing a series of mutations to adrenorphin. Compared with other natural opioid ligands, its sequence (FGGFMRRK) confers it maximum specificity and affinity for ACKR3 and minimum selectivity and affinity for other opioid receptors. LIH383 therefore binds to and blocks ACKR3, thereby modulating the availability of opioid peptides that can bind to classical opioid receptors in the brain and potentiating their natural painkilling and antidepressant properties. LIH383 is therefore a positive regulator of the opioid system. In a nutshell, LIH383 presents the following advantages: > Subnanomolar potency > High selectivity for ACKR3 > Short chain (8 amino acids) > Easy to synthesise/customise |
 | Device to determine the food shelf-life |
|
The Spanish National Research Council (CSIC) has designed a device to test the food oxidation, which applies real conditions of storage and transport combining light, temperature and dimensions of the device. This device allows determining the oxidative stability of the samples within a period of not more than one month, applying mild temperatures far below than the high temperatures commonly applied in Rancimat. Food enterprises interested in the utility model are searched to develop and market the compartment. |
 | Inhibitors of Viral Infectivity: Amphipathic Nucleoside Derivatives as Fusion Inhibitors |
|
A series of small pharmacological molecules have been discovered to be potent and non-cytotoxic inhibitors of viral fusion. The inhibitors act on the non-virally encoded lipids in the virion envelope. These molecules are rigid amphipathic compounds of inverted cone shape which locate to the outer leaflets of virion envelopes, creating a physical barrier to viral envelope and cell membrane fusion. These amphipathic nucleoside derivatives can serve as potential antiviral or therapeutic agents against herpes, HIV, influenza, hepatitis B & C, poxvirus and other DNA or RNA enveloped viruses. They can potentially be used as prophylactic ingredients in creams, lotions, gels and as antiviral disinfectants. |
Job opportunities
Introducing Innoget Jobs
Great innovation projects are built with
talented and creative people.
